Verastem is a biopharmaceutical company developing therapies for cancer, with a focus on programs targeting the RAS/MAPK pathway and related signaling in solid tumors. Its pipeline has centered on oral agents intended for patients with limited options in areas such as low-grade serous ovarian cancer and other RAS-driven diseases. The business model is clinical-stage drug development: value depends on trial outcomes, regulatory progress, and potential commercialization partnerships.
| Quarter | Revenue | YoY % | Earnings | YoY % |
|---|---|---|---|---|
| Q2 2025 | 2.1 | — | -25.9 | — |
| Q3 2025 | 11.2 | — | -98.5 | — |
| Q4 2025 | 17.5 | — | -32.9 | — |
| Q1 2026 | 18.7 | — | -36.6 | — |
| Q2 2026 | 40.1 | 1,775.4% | -34.7 | — |
All markets — KeepWinning global stock screener
Other companies on Nasdaq: General Fusion Group Ltd. (GFUZ), Prime Medicine, Inc. (PRME), AgomAb Therapeutics NV (AGMB), Matthews International Corporation (MATW), Grid Dynamics Holdings, Inc. (GDYN), Drugs Made In America Acquisition II Corp. (DMII)